Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333545 | 0.88 | MEN1 (0.56) | MEN1RAB9AKMT2ACNR2HSP90AA1 | |
| SCHEMBL3327170 | 0.85 | EPHX2 (0.53) | MEN1RAB9AKMT2AEPHX2CNR2 | |
| SCHEMBL13333547 | 0.84 | HSD11B1 (0.54) | MEN1RAB9AKMT2AEPHX2CNR2 | |
| SCHEMBL13333544 | 0.84 | CNR2 (0.49) | MEN1RAB9AKMT2AEPHX2CNR2 | |
| SCHEMBL3322044 | 0.83 | EPHX2 (0.54) | MEN1RAB9AKMT2AEPHX2CNR2 | |
| SCHEMBL3323551 | 0.83 | HSP90AA1 (0.56) | MEN1RAB9AKMT2ACNR2HSP90AA1 | |
| SCHEMBL3323184 | 0.82 | RAB9A (0.51) | MEN1RAB9AKMT2AEPHX2CNR2 | |
| SCHEMBL13333553 | 0.82 | CNR2 (0.50) | RAB9AEPHX2CNR2HSD11B1ALDH1A1 | |
| SCHEMBL4080995 | 0.82 | HPGD (0.58) | MEN1RAB9AKMT2AEPHX2ALDH1A1 | |
| SCHEMBL3322188 | 0.82 | ALDH1A1 (0.49) | MEN1RAB9AKMT2AEPHX2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | MEN1 3474/4885RAB9A 2432/4885KMT2A 3083/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | MEN1 2608/4885RAB9A 2176/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.